Most prostate cancers become castration-resistant in about two to three years. Castration-resistant prostate cancer grows even when testosterone levels are low. Nonmetastatic castration-resistant ...
SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with metastatic castration-resistant prostate ...
LONDON--(BUSINESS WIRE)--The global castration-resistant prostate cancer (CRPC) treatment market is expected to grow at a CAGR of more than 9% during the forecast period, according to Technavio’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results